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Accepted 31 October 2012AbstractObjective: The purpose of this studywas to evaluate the efficacy and feasibility of concomitant trocar-guided transvaginalmesh (TVM) surgery with a
midurethral sling (MUS) for treating women with advanced pelvic organ prolapse (POP) and stress urinary incontinence (SUI) or occult SUI (OSUI).
Materials and methods: Eighty-nine women with advanced POP and SUI or OSUI were retrospectively enrolled. The Total Prolift and Tension-
free Vaginal Tape-Obturator Systems were used for trocar-guided TVM surgery and MUS. Patients received regular follow-up at 1 week, and 1
month, 3 months, 6 months, and 12 months postoperatively, and then annually thereafter. The endpoints were the success rate for POP, and
perioperative and postoperative complications. Functional outcomes were the presence of voiding difficulty, persistent or de novo overactive
bladder symptoms, postoperative SUI, and paresthesia.
Results: The median follow-up period was 35 months (range, 12e50 months). Within the follow-up period, 84 patients (94.4%) were objectively
cured, five patients (5.6%) had vaginal apical mesh exposure, 29 individuals (32.6%) had persistent or de novo overactive bladder symptoms, six
individuals (22.5%) had de novo SUI (two were found by urodynamics), and nine individuals (10.1%) had voiding difficulties (two were found
by urodynamics). In addition, the vaginal hysterectomy group had greater blood loss, longer operation times, and a higher mesh erosion rate
compared to the uterine suspension group.
Conclusion: Concomitant trocar-guided TVM surgery and MUS with the use of total Prolift and Tension-free Vaginal Tape-Obturator offer good
efficacy in treating women with advanced POP and SUI or OSUI. The vaginal hysterectomy group had more perioperative complications.
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Pelvic organ prolapse (POP) and stress urinary inconti-
nence (SUI) often occur concomitantly. They are estimated to
occur in 15e80% of women with pelvic floor dysfunction [1].
The large variation in the prevalence may be due to the
absence of urine leakage in their daily activities, which only
becomes apparent during clinical evaluation or urodynamiccs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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(OSUI) is inconsistent in the medical literature, and is also
interchangeably referred to as masked, latent, hidden, iatro-
genic, or potential SUI [2]. The incidence of OSUI with
advanced POP is 36e80% with prolapse reduction [3e7].
There are three presentations in women with advanced POP:
(1) those without subjective or objective SUI; (2) those with
subjective or objective SUI; and (3) those without subjective
SUI, but which can be demonstrated objectively with the use
of prolapse reduction.
Postoperative SUI (POSUI) is still a challenging problem
during surgery for POP [8]. POSUI, which is also called de
novo SUI, refers to new symptomatic SUI after an operation. It
is estimated that 11e65% of continent patients with severe
POP will develop POSUI with no prophylactic anti-
incontinence procedures [9e12]. The large discrepancy may
come from different definitions of POSUI and heterogeneity
among study participants. Additional anti-incontinence pro-
cedures may prevent the occurrence of POSUI. However, the
challenge of dealing with women with POP is figuring out the
advantages and disadvantages of either concomitant or staged
anti-incontinence surgeries. Also, uncertainty of preoperative
evaluation methods exists in that they may be ambiguously
asymptomatic or show no leakage during prolapse reduction
testing in a patient with advanced prolapse [13].
Approaches include either concomitant or staged surgeries
with the aid of a prolapse reduction test [14]. It is desirable to
combine anti-incontinence and POP surgery at the same time
to minimize anesthetic risks and subject a patient to a single
convalescent period. Trocar-guided transvaginal mesh (TVM)
surgery with the use of a commercial kit that delivers a
polypropylene mesh through a vaginal approach has the ad-
vantages of minimal invasiveness and time efficiency [15,16].
Interest has been expressed in the concomitant use of trocar-
guided TVM surgery and MUS performed at the same time
as POP surgery [2,13].
The aim of this study was to evaluate the efficacy and
feasibility of trocar-guided TVM surgery and MUS to treat
women with advanced POP associated with SUI or OSUI. In
addition, we also evaluated the effects of a vaginal hysterec-
tomy (VH) at the time of trocar-guided TVM surgery on
perioperative complication rates, compared to the vault sus-
pension and uterine suspension group.
Materials and methods
After obtaining Institutional Review Board approval, we
reviewed medical records of women with advanced POP
associated with either SUI or OSUI who had undergone
concomitant trocar-guided TVM surgery and MUS, between
May 2007 and July 2010. Total Prolift and Tension-free
Vaginal Tape-Obturator Systems (Gynecare, Ethicon, Somer-
ville, NJ, USA) were used for trocar-guided TVM surgery and
the MUS procedures, respectively. Initially, 95 consecutive
patients were identified for inclusion, but six were excluded
because of loss to follow-up. In total, 89 women were
recruited for further analysis.A standard interview included information regarding age,
parity, diabetes mellitus (DM), body mass index (BMI), prior
pelvic reconstructive surgery or a hysterectomy, menopause,
and hormone replacement therapy status. Preoperatively, all
patients underwent a 1-hour pad test, cough stress test, and
multichannel urodynamic evaluation, according to a report on
good urodynamic practice by Schafer et al [17]. The cough
stress test was performed in a 45 lithotomy position at a
bladder volume of 150 mL and at maximum bladder capacity.
A diagnosis of urodynamic stress incontinence was made in
patients with a positive 1-hour pad test and observable leakage
during the cough stress test, without demonstrated detrusor
overactivity (DO) during cystometry. OSUI was defined as no
subjective SUI, with urine leakage only being demonstrated
after prolapse reduction during urodynamic testing.
All patients diagnosed with advanced POP [Stage III or IV,
according to the Pelvic-Organ-Prolapse Quantification (POP-
Q) system and 2010 International Urogynecological Associa-
tion/International Continence Society definitions] [18] and
SUI or OSUI underwent concomitant trocar-guided TVM
surgery and MUS. All procedures were performed by the se-
nior gynecologist with a specialty in pelvic reconstructive
surgery (K.-H. Huang) and experience with more than 800
trocar-guided TVM surgeries. General or spinal anesthesia
was applied according to the patient and anesthetist prefer-
ences. The operative procedures were as follows: first, the
patient received VH according to patient preference, followed
by trocar-guided TVM surgery with the total Prolift according
to the manufacturer’s guidelines. A vasoconstrictive agent
(300 mL) with diluted epinephrine was injected into both the
anterior and posterior vaginal walls to assist further dissection
and minimize blood loss (0.5 mL of 1 mg/mL adrenaline
added to 500 mL normal saline, for a total injection volume of
120e160 mL). After completing the trocar-guided TVM sur-
gery, TVT-O was performed with a separate vaginal incision
about 2.5 cm long from 1 cm below the external urethra to the
upper bladder neck. The TVT-O tape was inserted with an
inside-out approach, which was adjusted by Metzenbaum
scissors inserted between the suburethra and tape. Afterward, a
number 8 Hegar dilator (Richard Wolf Medical Instruments,
Rosemont, IL, USA) was inserted into the urethra to confirm
the patency of the urethra without bladder outlet obstruction
(BOO). A provocative stress test with manual suprapubic
pressure was used intraoperatively to facilitate adjustment of
the TVT-O. Cystoscopy was performed on all patients prior to
the end of surgery to exclude any bladder injury and confirm
the bladder integrity. All patients were given intravenous
prophylactic antibiotics, 1 g cefazolin administered 30 minutes
preoperatively and every 8 hours until 2e3 days
postoperatively.
The Foley catheter was removed 24e72 hours post-
operatively; then, patients were monitored with an intermittent
catheterization program. The program included an evaluation
of the postvoiding residual (PVR) volume with a bladder scan
(BVI 3000; Diagnostic Ultrasound, Bothell, WA, USA) every
4 hours. If the PVR volume was <50 mL or <20% of the
voided urine, the patient was discharged. If the PVR volume
Table 1
Patient characteristics (n ¼ 89).
Characteristic Mean  SD (minemax)
Age (y) 66.06  9.29 (43e86)
Parity 4.12  1.52 (2e9)
Body mass index 24.64  3.63 (12.49e32.89)
Comorbidity
Diabetes mellitus 16
Menopause 80
Hormone replacement therapy 38
Previous pelvic surgery
TAH 12
VH þ A-P repair 7
LAVH 1
Burch colposuspension 1
MUS 1
Type of urinary incontinence
Pure stress urinary incontinence 21
Occult stress urinary incontinence 42
Mixed stress urinary incontinence 26 (9 SUI, 17 OSUI)
AeP repair ¼ anterioreposterior colporrhaphy; LAVH ¼ laparoscopic-assis-
ted vaginal hysteroscopy; MUS ¼ midurethral sling; OSUI ¼ occult stress
urinary incontinence; SUI ¼ urinary incontinence; TAH ¼ total abdominal
hysterectomy; UI ¼ urinary incontinence.
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performed. If the PVR volume persistently exceeded 150 mL
for 1 day after removal of the Foley catheter, a cholinergic
agent and a blocker were prescribed. If the PVR volume
persistently exceeded 150 mL for 2 days after removal of the
Foley catheter, a Hegar dilator was inserted into the urethra
with a downward push on the proximal urethra. Women with a
PVR volume persistently above 100 mL for >7 days after
removal of the Foley catheter were taught clean intermittent
self-catheterization.
Patients were followed-up at 1 week, and 1 month, 3
months, 6 months, and 12 months postoperatively, and then
annually thereafter. During the first two visits, we checked
wound healing and PVR volumes. At each visit, we assessed
urinary and other relevant symptoms, and changes in the POP-
Q stage. All patients underwent a repeat urodynamic evalua-
tion at 6 months postoperatively.
The endpoints were the success rate for POP (recurrence of
prolapse defined as the most distal portion of POP of Stage II
or greater), perioperative and postoperative complications,
length of hospital stay, operative time, blood loss during sur-
gery, duration of the urine indwelling catheter, bladder or
ureter injury, bowel injury, and mesh exposure or extrusion
[19]. Functional outcomes were the presence of voiding dif-
ficulty, persistent or de novo overactive bladder (OAB)
symptoms, POSUI, and paresthesia (e.g., pain, numbness, or
weakness over the groin, vagina, buttocks, or thighs). Data
were analyzed using SPSS software Version 15.0 (SPSS Inc.,
Chicago, IL, USA). A paired-sample t test was used to
compare preoperative and postoperative data. If 25% of cells
had expected counts of <5 among the categorical variables,
Fisher’s exact test was performed. A p value <0.05 was
considered significant.
Results
Baseline characteristics for the 89 patients, including age,
parity, body mass index, previous pelvic surgery, and type of
urinary incontinence, are listed in Table 1. The median follow-
up period was 35 months (range, 12e50 months). The opera-
tive time, blood loss, length of hospital stay, mesh erosion, and
POP recurrence are listed in Table 2. Operative times in the VH
group, vault suspension group (with a previous hysterectomy),
and uterine suspension group (with uterine preservation) were
158.24  15.94 minutes, 129.55  19.45 minutes, and
132.19  21.74 minutes ( p < 0.0001); blood loss values
were 200.0  141.42 mL, 104.0  63.69 mL, and
141.35 113.21 mL ( p¼ 0.0344); and lengths of hospital stay
were 6.18 3.15 days, 5.85 1.42 days, and 5.40 1.27 days,
respectively ( p¼ 0.2625; Table 2). Trocar-guidedTVMsurgery
with VH had a longer operation time ( p < 0.01) and greater
blood loss ( p ¼ 0.03) compared to the vault suspension and
uterine suspension group. Mesh erosion was more commonly
encountered in theVH and vault prolapse group compared to the
uterine suspension group ( p¼ 0.01 by Fisher’s exact test). Five
of 89 (5.6%) patients had recurrent POP: three cases with Stage
II, one case with Stage III, and one case with Stage IV. Fouramong the five cases with POP recurrence occurred in the
uterine suspension group. Women at Stage III and Stage IV
received sacrospinous ligament fixation, with no subsequent
prolapse (Table 2). All of the POP-Q parameters significantly
improved at the 6-month follow-up, and all p< 0.001 (Table 3).
All 89 patients were regularly followed-up with an urody-
namic study at 6 months postoperatively. Among them, uro-
dynamic parameters were available in 69 patients (20 patients
were unavailable due to personal reasons) and are listed in
Table 4. Postoperatively, patients had a higher maximum flow
rate (Qmax) and mean flow rate (Qmean), with p < 0.001 and
p < 0.013, respectively; lower PVR volume and maximum
urethral closure pressure (MUCP), with p < 0.001 and
p < 0.009, respectively; and no significant changes in the first
sensation of bladder filling, functional urethral length, or
maximum cystometric capacity.
Perioperative and postoperative complications were also
evaluated and are listed in Table 5. There were two vaginal
hematomas; one was uneventful after conservative manage-
ment; the other vaginal hematoma measured 6 cm  5 cm and
was located beneath the bladder base. This patient received a
blood transfusion, antibiotics, prolonged hospital stay (18
days, the longest in this study), and an indwelling urinary
catheter for 3 weeks. Postoperatively, five of 89 (5.6%) pa-
tients had vaginal apical mesh exposure, and all of the epi-
sodes were asymptomatic, without infection signs. Of these,
three cases underwent local excision for the exposed portion of
the mesh (<1 cm) with no further mesh erosion afterward.
One recovered well after topical vaginal estrogen cream
application. The remaining patient refused local excision and
topical vaginal estrogen cream. She had persistent asymp-
tomatic mesh exposure and no infection signs.
Twenty-nine of 89 (32.6%) patients had postoperative
persistent or de novo OAB symptoms, and symptoms were
resolved with antimuscarinic treatment. DO was demonstrated
Table 2
Operative time, blood loss, length of hospital stay, mesh erosion, and POP recurrence among the three groups (n ¼ 89).
Totala Group 1b VH Group 2c Vault suspension Group 3d Uterine suspension p
n ¼ 89 17 (19.1) 20 (22.5) 52 (58.4)
Operative time (min) 136.57  2.70 (79e205) 158.24  15.94 (130e180) 129.55  19.45 (80e161) 132.19  21.74 (79e205) <0.01
Blood loss (mL) 144.16  113.64 (30e600) 200.00  141.42 (50e550) 104.00  63.69 (30e250) 141.35  113.21 (50e600) 0.03
Hospital stay (d) 5.65  1.81 (4e18) 6.18  3.15 (4e18) 5.85  1.42 (4e9) 5.40  1.27 (4e9) 0.26
Mesh erosion 5/89 (5.6) 3/17 (17.6) 2/20 (10.0) 0/52 (0) 0.01e
POP recurrence 5 (5.6) 1/17 (5.9), Stage II 0/20 (0) 4/52 (7.7) Stage IV, III, II (2) NA
Data are presented as mean  SD (minemax) or n/N (%).
NA ¼ not applicable; POP ¼ pelvic organ prolapse; SD ¼ standard deviation; TVM ¼ transvaginal mesh; VH ¼ vaginal hysterectomy.
a All patients received tension-free vaginal tape as a midurethral sling; b Group 1, VH þ TVM; c Group 2, vault suspension þ TVM; d Group 3, uterine
suspension þ TVM; e According to Fisher’s exact test.
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Nine of 89 patients (32.7%) had voiding difficulties with
subjective symptoms, for example, difficult emptying, a
sensation of incomplete voiding, hesitancy, weak or prolonged
flow, intermittent flow, postvoiding dribbling, and the need to
change position to facilitate micturition postoperatively, and
only two of them were demonstrated by the postoperative
urodynamic study. In our study, 55 of 57 (96.5%) patients with
preoperative voiding difficulty were cured. One patient had the
MUS removed 18 months postoperatively due to detrusor
underactivity, and no recurrent SUI was found at follow-up.
There were 20 of 89 (22.5%) patients with POSUI; eight of
them had preoperatively severe SUI (1-hour pad test > 10 g);
none considered their urinary leakage bothersome, and no
additional anti-incontinence surgery was needed. Six of them
were diagnosed by objective urodynamics, and none of them
had intrinsic sphincter deficiency with low MUCP (Table 5).Table 4
Comparison of the 1-hour pad test and urodynamic parameters between theDiscussion
We reported the efficacy and feasibility of concomitant
trocar-guided TVM surgery and MUS with the use of total
Prolift and TVT-O in treating women with advanced POP and
SUI or OSUI. However, the optimal use of anti-incontinence
surgery during pelvic reconstructive surgery remains a matter
of debate [20,21]. Performing concomitant trocar-guided TVM
surgery and MUS surgery has the advantage of using the same
route without other additional incisions. The updated 2010
American Urological Association Guidelines for Surgical
Management of Female Stress Urinary Incontinence reported aTable 3
Comparison of POP-Q parameters between preoperative conditions and those
at 6 months postoperatively (n ¼ 89).
POP-Q Preoperative Postoperative p
Aa 2.96  0.26 2.83  0.83 <0.001
Ba 6.03  1.62 2.80  0.93 <0.001
C 5.97  1.70 6.89  2.58 <0.001
Ap 2.72  0.80 2.98  0.13 <0.001
Bp 4.91  2.39 3.01  0.24 <0.001
TVL 7.72  1.20 8.18  0.97 <0.001
Gh 5.40  0.85 3.89  0.64 <0.001
Pb 2.84  0.69 3.70  0.56 <0.001
Data are presented as mean  SD.
POP-Q ¼ pelvic organ prolapse quantification.comparable cure rate and safe use of concomitant surgery for
SUI and POP in appropriately selected women [22].
We recently reviewed the literature to elucidate MUS as a
prophylactic procedure during POP surgery [13]. Liang et al
[23] recommended TVT for OSUI patients undergoing
reconstructive surgery if there was a positive pessary reduction
test. The POSUI was 9.4% (3/32) in the TVT group compared
to 64.7% (11/17) in the no-TVT group when the pessary test
was positive [23]. On the contrary, de Tayrac et al [24]
opposed the use of TVT in OSUI, because TVT had a
similar effect (0%, 0/11) in POSUI, compared to the control
group (12.5%, 1/8; p > 0.05), with a higher risk, for example,
more voiding dysfunction (27.3%, 3/11 vs. 0%, 0/8; p > 0.05).
The above two TVT studies with a controlled non-intervention
arm reported differing results with limited case numbers.
Thereafter, a randomized controlled trial by Meschia et al [25]
reported significantly lower subjective and objective POSUI
rates in the TVT group compared to the endopelvic fascia
plication group. Araki et al [26] reported the protective effect
of a transobturator midurethral sling (TOT) for women with
OSUI. POSUI developed in none of the concomitant TOT
group and developed in 62% (8/13) of the non-TOT group.
Iatrogenic BOO might potentially increase, because the
number of patients undergoing anti-incontinence surgery has
dramatically increased in recent years [27,28]. BOO was re-
ported to occur in 5e20% of patients undergoing anti-
incontinence surgery [29]. BOO patients can present with
subtle obstructive or irritative symptoms, for example, bendingpreoperative and postoperative conditions (n ¼ 69/89).
Preoperative Postoperative p
1-h pad test (g) 6.22  15.18 0.23  0.93 0.002
Qmax (mL/s) 14.97  10.92 21.46  8.79 <0.001
Qmean (mL/s) 6.61  5.16 8.54  3.84 0.013
PVR (mL) 83.59  52.97 23.52  28.56 <0.001
FS (mL) 145.06  46.20 157.42  76.36 0.185
MCC (mL) 335.83  86.73 355.17  89.97 0.104
MUCP (cmH2O) 69.20  27.53 59.02  23.44 0.009
FUL (cm) 33.43  9.83 31.23  8.77 0.147
Data are presented as mean  SD.
FS ¼ first sensation of bladder filling; FUL ¼ functional urethral length;
MCC ¼ maximum cystometric capacity; MUCP ¼ maximum urethral closure
pressure; PVR ¼ post-void residual urine; Qmax ¼ maximum flow rate;
Qmean ¼ mean flow rate.
Table 5
Perioperative morbidities and postoperative complications (n ¼ 89).
n (%)
Perioperative morbidity
Blood transfusion 1 (1.1)
Hematoma 2 (2.2)
Bladder or ureter injury 0
Bowel injury 0
Duration of urine indwelling
catheterization (d)
1e3 78 (87.6)
4e5 7 (7.9) (ICPa  medical treatment)
6 4 (4.5%) (2 urethral downward with Hegar
dilator, 1 CISC, 1 prolonged indwelling
catheterizationb)
Postoperative complication n (%) (description of management)
Mesh exposure 5 (5.6) (3 excision, 2 vaginal estrogen cream)
Abnormal sensation 8 (9.0) (no analgesics needed)
OAB symptoms 29/89 (32.6)
Persistent OAB 20/26 (77.9) (10 DO on urodynamics)
De novo OAB 9/63 (14.3)
Voiding difficulties 9 (32.68) (2 evidenced on urodynamics)
POSUI 20 (22.5) (6 evidenced on urodynamics)
CISC ¼ clean intermittent self-catheterization; ICP ¼ intermittent catheteri-
zation program; OAB ¼ overactive bladder; POSUI ¼ postoperative stress
urinary incontinence.
a ICP was associated with a bladder scan and sterilized intermittent cathe-
terization; b Indwelling urinary catheterization for 3 weeks.
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An elevated detrusor pressure not commensurate with the flow
indicates an obstructive element in a non-neurogenic patient
by urodynamics; however, threshold criteria for obstruction
continue to be debated [30]. Vaginal tape can be adjusted
according to an intraoperative provocative stress test [31,32].
Yet, the technique can cause potential overtightening of the
tape. In our study, we used a Hegar dilator inserted into the
urethra to push the proximal urethra downward during the
early postoperative phase. In case of postoperative voiding
difficulty due to BOO occurring after anti-incontinence sur-
gery, a salvage procedure, for example, cutting the synthetic
suburethral sling would likely improve obstructive symptoms,
but not irritative symptoms [33].
It is difficult to determine the etiology of postoperative
urinary retention (PUR) even after a delicate preoperative
urodynamic study. There are various explanations for this, for
example, detrusor underactivity, undue urethral elevation,
urethral stricture, anxiety, or excessive tension of MUS [29].
Although medication with cholinergic and a blocker was
helpful in immediate PUR cases in our study, use of drugs that
directly or indirectly act as parasympathomimetics remains in
dispute due to their low efficacy and high prevalence of side
effects [34]. Sterile or clean intermittent catheterization can
also be helpful in relieving symptoms. Prolonged indwelling
catheterization can be used for cases with prolonged PUR.
We attributed our low morbidities to a completed learning
curve during the conduct of this study [35]. Mesh erosion or
exposure has raised great concerns directly related to the
insertion of prostheses [19]. DM is a possible risk factor for
mesh erosion; however, no mesh exposure patient had DM inour study. Therefore, patients with well-controlled DM do not
have an increased risk of mesh exposure. Mesh exposure can
be managed with simple full-thickness excision of the exposed
mesh, generally as an outpatient procedure, with resolution of
bothersome symptoms [36]. As a result of potential serious
consequences, complex excisions should be performed in
skilled centers [37]. Mesh exposure did not occur in our
uterine suspension group, compared to the VH group or vault
suspension group. Uterine preservation, avoiding anterior
inverted “T” incisions, placing the mesh beneath the full
thickness of the vaginal wall, and suturing the vaginal wall in
two layers were proposed to reduce the occurrence of mesh
exposure [36]. Four of five POP recurrences occurred in the
uterine suspension group. The reason for the discrepancy be-
tween the group with and that without VH remains unclear.
Lin et al [38] proposed the presence of an elongated cervix,
whereas Jeon et al [39] attributed POP recurrence to the mesh,
instead of a hysterectomy.
In concordance with the report of Ek et al [40], we found a
decrease in MUCP and PVR volume, and increases in Qmax
and Qmean after surgery, which may have resulted in more
POSUI after TVM surgery, compared to colporrhaphy. Aungst
et al [15] reported POSUI as high as 24.3% after trocar-guided
TVM surgery. In addition to an intrinsic sphincter deficiency,
age, and DM, we further identified severe preoperative SUI as
a risk factor for POSUI. It is currently not our practice to
perform a routine concomitant anti-incontinence procedure on
stress-continent women undergoing trocar-guided TVM sur-
gery unless there is preoperative evidence of SUI or OSUI. It
demands emphasis of the potential risks of POSUI in preop-
erative counseling and explaining that interval outpatient
therapies are available to manage new-onset SUI should it
occur and become bothersome [40].
The prevalence of OAB symptoms is greater in patients
with POP, and POP induces OAB symptoms and DO signs
[41]. Patients with preoperative OAB symptoms are more
likely to have persistent symptoms postoperatively. In our
series, preoperative OAB was found to be a predictor of
postoperative OAB, that is, persistent (20/26, 77%) versus de
novo (9/63, 14%) OAB symptoms. BOO may play an impor-
tant role in postoperative OAB [41e43]. It is unclear which
risk factors predict whether OAB symptoms will disappear.
DO was thought to be a predictor [41,44]. All cases with
preoperative DO had persistent OAB. By contrast, Fletcher
et al [45] reported a significantly lower preoperative detrusor
pressure at maximum flow (PdetQmax; 17 vs. 24 cmH2O,
p ¼ 0.042) [45]. An increase in postoperative OAB symptoms
(14%) was noted in the current study. However, the etiology of
de novo OAB symptoms remains controversial, and the posi-
tion and tightness of the tape may play an important role.
One limitation of the present study was that we did not
assess the postoperative quality of life or sexual dysfunction,
although a higher rate of dyspareunia following trocar-guided
TVM surgery was anticipated. Second, the case numbers of
our study were not large enough to be randomized into a group
of MUS versus non-MUS at the time of trocar-guided TVM
surgery.
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and MUS offer good efficacy and feasibility in treating
women with POP and SUI or OSUI. However, concerns
should be raised regarding potential harmful consequences
due to such an intervention, particularly technique-related
morbidity (bleeding, organ injury, and mesh exposure).
One single treatment strategy cannot fit every woman.
Certainly, patient input should be taken into account as well,
and a frank discussion of the pros and cons of concomitant
surgery should occur between the surgeon and patient prior
to surgery.References
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